Diabetes, insulin, and risk of cancer

被引:36
作者
Schiel, R.
Beltschikow, W.
Steiner, T.
Stein, G.
机构
[1] Inselklin Heringsdorf GmbH, Dept Diabet & Metab Dis, D-17424 Seebad Heringsdorf, Germany
[2] Univ Jena, Sch Med, Dept Urol, D-6900 Jena, Germany
[3] Univ Jena, Sch Med, Dept Internal Med 3, D-6900 Jena, Germany
来源
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY | 2006年 / 28卷 / 03期
关键词
cancer; carcinoma; diabetes mellitus; HbA1c; insulin therapy; malignancy;
D O I
10.1358/mf.2006.28.3.985230
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Up to now, the studies involving diabetes mellitus and malignancies show controversial results: Many of them have found incidences of malignancies that were comparable or even lower than those in nondiabetic subjects; others conclude that diabetes mellitus is linked to a higher incidence of malignancies and/or a predictor of mortality from cancer. Insulin and its precursors, pro- and pre-proinsulin, have been shown to have some homology to the insulin-like growth factors, but, moreover they have some affinity to bind at receptors of the tumor growth factor and some hybrids too. Hence, an association between diabetes mellitus, insulin, hyperinsulinaemia, and carcinogenesis appears plausible. On the other hand, diabetes mellitus can influence different hormone levels. In some tumor entities, such as prostate carcinoma, this effect can somewhat counterbalance the direct mitogene effect of insulin and its precursors. All in all, as a result of the complexity of these mechanisms and the differences between the tumor entities, the question whether diabetes mellitus is associated with an increased or a reduced risk for the development and in respect of the prognosis of cancer cannot be answered. The only way to give some answer is to focus on specific tumor entities: It seems that diabetes mellitus and/or hyperglycaemia are independent risk factors and/or predictors at least in respect of cancer of the colon, pancreas, female breast, endometrium, and, in men, of the liver and bladder. However, most of these data were assessed in patients with type 2 diabetes mellitus. This makes it highly questionable whether the data can easily be transferred to patients with type I diabetes. Moreover, additional potential limitations are that most of the studies do not focus on the treatment modality or the race of participants. In conclusion, UP to the present, we have an increased risk for some and a reduced risk for other tumor entities, but still, we cannot give the general answer. (c) 2006 Prous Science. All rights reserved.
引用
收藏
页码:169 / 175
页数:7
相关论文
共 93 条
[41]   Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor [J].
IshShalom, D ;
Christoffersen, CT ;
Vorwerk, P ;
SacerdotiSierra, N ;
Shymko, RM ;
Naor, D ;
DeMeyts, P .
DIABETOLOGIA, 1997, 40 (Suppl 2) :S25-S31
[42]   INSULIN-LIKE GROWTH FACTOR-I - ACTION AND RECEPTOR CHARACTERIZATION IN HUMAN PROSTATE-CANCER CELL-LINES [J].
IWAMURA, M ;
SLUSS, PM ;
CASAMENTO, JB ;
COCKETT, ATK .
PROSTATE, 1993, 22 (03) :243-252
[43]   ALTERED RESPONSES TO ANDROGEN IN DIABETIC MALE-RATS [J].
JACKSON, FL ;
HUTSON, JC .
DIABETES, 1984, 33 (09) :819-824
[44]  
Janeczko D, 1998, Pol Arch Med Wewn, V100, P165
[45]   Fasting serum glucose level and cancer risk in Korean men and women [J].
Jee, SH ;
Ohrr, H ;
Sull, JW ;
Yun, JE ;
Ji, M ;
Samet, JM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (02) :194-202
[46]   Cancer statistics, 2003 [J].
Jemal, A ;
Murray, T ;
Samuels, A ;
Ghafoor, A ;
Ward, E ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2003, 53 (01) :5-26
[47]  
Kath R, 2000, J CANCER RES CLIN, V126, P412
[48]  
Kath R., 1990, CANCER THER CONTROL, V1, P179
[49]   INSULIN-LIKE AND INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR TYROSINE-KINASE ACTIVITIES IN HUMAN RENAL-CARCINOMA [J].
KELLERER, M ;
CORLETA, HVE ;
MUHLHOFER, A ;
CAPP, E ;
MOSTHAF, L ;
BOCK, S ;
PETRIDES, PE ;
HARING, HU .
INTERNATIONAL JOURNAL OF CANCER, 1995, 62 (05) :501-507
[50]  
La Vecchia C, 1997, CANCER EPIDEM BIOMAR, V6, P1007